Toggle Offcanvas
...
 
Dapagliflozin Tenders

Dapagliflozin Tenders

View Dapagliflozin tenders, RFPs and contracts. Bid on readily available Dapagliflozin tenders with the best and most comprehensive tendering platform, since 2002.
Dapagliflozin is a medication used to lower blood sugar levels in people with type 2 diabetes. It works by helping the kidneys remove excess glucose from the body through urine, making it easier to control blood sugar levels.

Bidding for Dapagliflozin tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Dapagliflozin.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Dapagliflozin market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Dapagliflozin tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

46 Live Notices for Dapagliflozin Tenders

Showing 1 to 20

Open House Contracts 2025-1
country Germany
posting date11 Mar 2025
deadline02 May 2025
Open House Contracts 2025-1
country Germany
posting date11 Mar 2025
deadline02 May 2025
Buy Dapagliflozin 10Mg Tab
country Jordan
posting date03 Mar 2025
deadline23 Mar 2025
Buy Dapagliflozin 10Mg Tab
country Jordan
posting date03 Mar 2025
deadline23 Mar 2025
Deruxtecan Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 160 MG Pharmaceutical Form: Injectable Lyophilized Powder; Crizotinib Concentration*: 250 MG; Enzalutamide Concentration: 40 MG; Ocrelizumab Concentration: 30 MG/ML Pharmaceutical Form: Solution for Infusion; Dapagliflozin Concentration: 10 MG; Evolocumab Concentration: 140 MG/ML Pharmaceutical Form: Injectable Solution Additional: With Applicator Pen; Ruxolitinib Concentration
country Brazil
posting date01 Mar 2025
deadline12 Mar 2025
Pharmaceutical Discount Agreements From February 1, 2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date12 Dec 2024
deadline02 Dec 2026
Pharmaceutical Discount Agreements From February 1, 2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date12 Dec 2024
deadline02 Dec 2026
Medicines Containing The Active Ingredient Dapagliflozin (Atc: A10Bk01)
country Germany
posting date27 Aug 2024
deadline31 Jul 2026
Medicines Containing The Active Ingredient Dapagliflozin (Atc: A10Bk01)
country Germany
posting date27 Aug 2024
deadline31 Jul 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dapagliflozin + Metformin, Atc A10Bd15 (Obo) For The Period 01.10.2024 - 30.09.2026
country Germany
posting date19 Aug 2024
deadline05 Aug 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dapagliflozin + Metformin, Atc A10Bd15 (Obo) For The Period 01.10.2024 - 30.09.2026
country Germany
posting date19 Aug 2024
deadline05 Aug 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dapagliflozin, Atc A10Bk01 (Obo) For The Period 01.10.2024 - 30.09.2026
country Germany
posting date19 Aug 2024
deadline05 Aug 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dapagliflozin, Atc A10Bk01 (Obo) For The Period 01.10.2024 - 30.09.2026
country Germany
posting date19 Aug 2024
deadline05 Aug 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dapagliflozin, Atc A10Bk01 (Obo) For The Period 01.10.2024 - 30.09.2026
country Germany
posting date17 Aug 2024
deadline05 Aug 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dapagliflozin, Atc A10Bk01 (Obo) For The Period 01.10.2024 - 30.09.2026
country Germany
posting date17 Aug 2024
deadline05 Aug 2026
Open House Original Discount Agreements 2023-20 - Metformin/Dapagliflozin (Drug Combination)
country Germany
posting date17 Jun 2023
deadline31 Jul 2025
Open House Original Discount Agreements 2023-20 - Metformin/Dapagliflozin (Drug Combination)
country Germany
posting date17 Jun 2023
deadline31 Jul 2025
Open House Original Discount Agreements 2023-20 - Metformin/Dapagliflozin (Drug Combination)
country Germany
posting date17 Jun 2023
deadline31 Jul 2025
Open House Original Discount Agreements 2023-20 - Metformin/Dapagliflozin (Drug Combination)
country Germany
posting date17 Jun 2023
deadline31 Jul 2025
Open House Original Discount Agreements 2023-20 - Metformin/Dapagliflozin (Drug Combination)
country Germany
posting date15 Jun 2023
deadline31 Jul 2025

Share Share this page